

NPPA/ Drug pricing**Publication: Millennium Post****Edition: National****Date: September 9, 2014****Headline: [Life-saving drug vanishes after govt introduces price control](#)**

Synopsis: The decision of the National Pharmaceutical Pricing Authority (NPPA) to control the price of life saving drugs has led to its disappearance from the retail market. In a reality test conducted by Millennium Post over the shortage of drugs, it has come to light that Albumin, which is administered intravenously to patients in critical care situations in hospitals, is not available on the shelves of retail shops across the country.

Patents/ IPR/ Compulsory licensing**Publication: The Economic Times****Edition: National****Date: September 9, 2014****Headline: [IPR policy on the cards to protect national interests, says Nirmala Sitharaman](#)**

Synopsis: India has proposed a national intellectual property rights (IPR) policy to safeguard its interests and bring clarity to existing laws ahead of Prime Minister Narendra Modi's visit to the US this month. "We are going to have a national IPR policy in place soon. It will not be restrictive but promote national interest. India has well-established IPR laws, but it is important to spell it out in the form of a policy for the entire world to see," commerce & industry minister Nirmala Sitharaman said at a briefing to mark the government's first 100 days.

Similar reports in-**Mint- [Policy on intellectual property rights likely in six months](#)****The Times of India- [Govt to frame IPR policy, set up think tank: Sitharaman](#)****Business Standard- [Ahead of Modi's US visit: Govt says will hammer out IPR policy](#)****The Hindu Business Line- [Sitharaman: Govt working on new policy on intellectual property rights](#)****The Hindustan Times- [Intellectual property rights policy in 6 months](#)****The Hindu- [IPR policy soon, says Minister](#)****The Financial Express- [Govt to formulate IPR policy, set up think tank, says Nirmala Sitharaman](#)****The Indian Express- [Govt signals IPR recast ahead of Modi's US visit](#)****The Financial Chronicle- [Think-tank to devise IPR policy](#)****Deccan Chronicle- [Government to come out with IPR policy: Commerce and Industry Minister](#)****NDTV- [Government Working on Intellectual Property Rights Policy: Nirmala Sitharaman](#)****Publication: Mint****Edition: Online****Date: September 8, 2014****Headline: [Court grants Novartis temporary injunction against Ranbaxy](#)**

Synopsis: The Delhi high court on Monday restrained Ranbaxy Laboratories Ltd from manufacturing and selling a copycat version of vildagliptin, an anti-diabetes medicine patented by Swiss drug maker Novartis till December 2019. Vildagliptin and its formulations are sold under trade names Galvus, GalvusMet and Eucreas by Novartis as well as companies that have obtained permits from it. Novartis sold \$577 million worth of Galvus and \$707 million of GalvusMet.

Publication: The Indian Express

Edition: Online

Date: September 9, 2014

Headline: [Novartis drags DRL to US court for patent violation](#)

Synopsis: Switzerland-based Novartis AG and Novartis Pharmaceuticals Corporation (NPC) have sued Dr Reddy's Laboratories in a the United States' District Court for the District of Delaware for a patent infringement action on the drug Gleevec. The action relates to an Abbreviated New Drug Application (ANDA) filed by DRL with the United States Food and Drug Administration (US FDA) for approval to market generic versions of Novartis' Gleevec, which is used as a targeted therapy for treating certain types of leukaemia. Gleevec is one of the best selling drugs of Novartis clocking sales revenues worth over \$4 billion.

Clinical trials/ R&D

Publication: Business Standard

Edition: National

Date: September 9, 2014

Headline: [As red tape grows, pharma research flees India](#) (editorial)

Synopsis: Piramal Enterprises, the Piramal group's flagship company operating primarily in the healthcare sector, has decided to close its Mumbai drug research and development (R&D) unit, its largest in the country. With this, the list of Indian drug makers that have either downsized their R&D work or have moved it outside India has got longer. Ten years ago, India wanted to become the hub for drug research. Some scientists said they could discover and develop a new molecule for less than \$100 million - a tenth of what it cost abroad then. Today, much of that enthusiasm seems to have dissipated. Piramal Enterprises Vice-chairperson Swati Piramal recently told Reuters that the group has "lost the India advantage". The only option left, she said, was to invest in R&D abroad.

Publication: The Times of India

Edition: National

Date: September 9, 2014

Headline: [Doctors' new weapon: Drug that fights flu in single dose](#)

Synopsis: Doctors could soon have a new weapon to fight the flu virus as US researchers have found a single-dose influenza drug that can safely and effectively relieve influenza symptoms. An analysis of clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms, researchers said.

Similar report in-

Business Standard- [New drug may fight flu in one dose](#)

Health Ministry

Publication: Business Standard

Edition: Online

Date: September 8, 2014

Headline: [Dhaka WHO regional meet to focus on cooperation Dr Harsh Vardhan to sign MoU with Bangladesh on traditional medicine](#)

Synopsis: A Memorandum of Understanding (MoU) on cooperation on traditional medicine and homoeopathy is to be signed between India and Bangladesh this week. This is the age of holistic medicine. No single line of treatment is supreme. I intend giving the ancient wisdom contained in our evidence-based medicine pride of place in public health, Union Health Minister Dr Harsh Vardhan, said

today before leaving for Dhaka to attend the 67th general meeting of World Health Organisation (WHO)s Regional Committee between September 9 and 12.

Publication: Daily News & Analysis

Edition: Online

Date: September 8, 2014

Headline: [Mass awareness should be generated on eye donation, says Union Health Minister Harsh Vardhan](#)

Synopsis: Union Health Minister Dr Harsh Vardhan has said that he would request the Ministry of Human Resource Development (HRD) to include in school text books passages and essays that generate in young children a positive attitude towards organ donation in general and eye (cornea) donation in particular. While speaking here at the centenary celebrations of Shroff's Charity Eye Hospital yesterday he stated that the ongoing National eye donation Fortnight that started from August 25 and would continue till today, September 8, an annual event organised by the National Programme for Control of blindness, is meeting with good response in a large number of states, including the national capital. It is now felt that youngsters should be exposed to the enormity of the problem of blindness in India and their responsibility to contribute to its end.

Publication: Business Standard

Edition: National

Date: September 9, 2014

Headline: [Strategy needed to reduce youth alcohol use: Vardhan](#)

Synopsis: Health Minister Harsh Vardhan, on a visit to Bangladesh for the World Health Organization (WHO) regional committee meeting, said the excessive consumption of alcohol had significant impact on the youth population of India and he planned to learn a strategy to reduce its use. "The immoderate consumption of alcohol affects the youth population of India greatly. It is one of the four most common modifiable and preventable risk factors for non-communicable diseases. I look forward to learning more about the strategy," Vardhan said.

Modi government

Publication: The Economic Times

Edition: Online

Date: September 8, 2014

Headline: [Now a strong government will be talking to Barack Obama: Sushma Swaraj](#)

Synopsis: Ahead of the much-anticipated summit talks between Prime Minister Narendra Modi and US President Barack Obama in Washington, External Affairs Minister Sushma Swaraj Monday said "this time a strong government will be talking" to the US. Answering a question in her first press conference since taking over the ministry in May, Sushma Swaraj said the Modi-Obama talks on Sep 30 will see a "strong government" interacting with the US, "which will make all the difference".

Similar reports in-

The Hindustan Times- [Power-packed agenda awaits Modi in US](#)

The Hindu Business Line- [Visa will top agenda when Modi meets Obama](#)

The Hindu- [Modi diplomacy proactive, strong and sensitive: Minister](#)

Publication: The Economic Times

Edition: Online

Date: September 9, 2014

Headline: [PM Modi's 100 days: Sushma Swaraj talks tough on Pakistan, China and US](#)

Synopsis: She may have been quiet for the first 100 days of the Narendra Modi government but Sushma

Swaraj was in an aggressive mood on Monday at her first media briefing as foreign minister, ticking off Pakistan and China and promising the US that a stronger Indian government would now be speaking to President Barack Obama. Swaraj said the catchphrase for her tenure was "fast-track diplomacy" and said it had three faces - proactive, strong and sensitive. "This time a strong government will be talking to Obama. That will be the main difference," Swaraj said, when asked how different the Modi government's approach would be from the previous UPA administration as the Prime Minister travels to the US later this month.

Publication: The Hindu Business Line

Edition: Online

Date: September 8, 2014

Headline: [U.S. CEOs may participate in Vibrant Gujarat Summit next year](#)

Synopsis: Evincing interest in the forthcoming Vibrant Gujarat Summit as a global business platform, the CEOs of some American companies are likely to attend the mega event here in January 2015. A State Government delegation, led by Bharat Lal, Resident Commissioner, New Delhi, visited Canada and the US cities, including Chicago and Illinois, last week, to meet with the business community, investors and NRIs in this regard, a government official said here on Monday.

Similar report in-

The Telegraph- [Eleven years on, US wakes up to Gujarat](#)

FDA/ Drug quality

Website: Pharmabiz

Edition: Online

Date: September 9, 2014

Headline: [Indian pharma needs to aim at continuity in learning to sustain a culture of quality: SM Mudda](#)

Synopsis: Indian pharma industry needs to aim at creating continuity in learning to sustain a culture of quality, said SM Mudda, executive director, Technical & Operations, Micro Labs and member, Committee of Administration, Pharmexcil. A challenge in the pharma industry today, not just in India but globally, is the concern on quality and enabling and implementing new learnings in quality management systems, he added.

Website: Pharmabiz

Edition: Online

Date: September 9, 2014

Headline: [Gujarat FDCA increases sample testing of drugs by threefold](#)

Synopsis: The Gujarat Food and Drug Control Administration (FDCA) has witnessed a significant increase in the number of sample testing by three fold this year, enabling them to safeguard healthcare needs of its citizens further. It is understood that the drug regulating agency has tested more than 9000 drug samples this year alone compared to 3000 drug sampling done in the previous years.

Publication: Business Standard

Edition: Online

Date: September 8, 2014

Headline: [Indian drug cos hopeful of Peru relaxing norms](#)

Synopsis: After Argentina allowed import of Indian finished drugs last month, thus opening the gates to a \$6 billion potential pharma market for Indian formulation makers, according to officials at the Pharmaceutical Export Promotion Council (Pharmexcil) senior officials from Peru are likely to visit soon to gather details about the loan-licensing system of manufacturing here.

Publication: The Hindustan Times

Edition: Online

Date: September 8, 2014

Headline: [AIIMS to provide doorstep healthcare to Bhopal's poor](#)

Synopsis: With an effort to provide free doorstep healthcare to the city's poor, the All India Institute of Medical Sciences (AIIMS) Bhopal will soon rope neighbourhood residents to coordinate between the doctors and the slum dwellers. Under the initiative, a local resident from a selected neighbourhood will be trained as a 'slum mobile dost (friend)', officials said Saturday. Doctors at the AIIMS, who have launched a pilot project at a settlement close to the institute, said the venture besides providing immediate healthcare will also map the dwellers medical history.

Public health

Publication: The Indian Express

Edition: National

Date: September 9, 2014

Opinion piece: Pushpa Sundar, author of 'Business and Community: The Story of Corporate Social Responsibility in India'

Headline: [Half the sanitation battle](#)

Synopsis: It is heartening that several ministries and companies have responded with alacrity to the prime minister's call for the construction of toilets. It is indicative not only of the PM's authority but also of the fact that the concern is widely shared. The ministry of rural development has proposed to increase the allocation for constructing individual, school, anganwadi and community toilets in rural areas. But it has proposed to delink toilet construction from the MGNREGA. This is a pity because toilet construction is an essential and visible contribution to a community's development — better than digging for roads, which is best left to professional agencies.

General Industry

Publication: The Economic Times

Edition: Online

Date: September 8, 2014

Headline: [Cipla announces commercial tie-up with UK's S&D Pharma](#)

Synopsis: Pharmaceutical firm Cipla today announced commercial collaboration with UK-based S&D Pharma in the Czech Republic and Slovakia. In a BSE filing, Cipla said this collaboration will enable it to focus on its core therapy areas, while S&D Pharma will be the key partner for generics. Under the collaboration, Cipla will drive its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head, the company said in a statement.

Similar reports in-

Business Standard- [Cipla ties up with S&D Pharma to enter Czech Republic & Slovakia](#)

The Hindu- [Cipla ties up with S&D Pharma to enter Czech Republic, Slovakia](#)

Business Today- [Cipla announces commercial tie-up with UK-based S&D Pharma](#)

Pharmabiz- [Cipla ties up with S&D Pharma to enter Czech Republic and Slovakia with affordable high quality alternatives](#)

Publication: The Tribune

Edition: National

Date: September 9, 2014

Headline: Zero medical error (editorial) (link unavailable, scan attached)

Synopsis: Healthcare, whether in the metros with 5-star multi-speciality hospitals or in the remote rural areas, is a nightmare. There is only one doctor per 1,700 citizens in India, much below the World Health Organisation (WHO) stipulated ratio of 1:1,000. Even when healthcare is accessible, quality is not ensured. Fewer than 1 per cent Indian hospitals are accredited for maintaining standards. Thousands of primary health centres, nursing homes and clinics have not yet come under the scanner. Unfortunately, in the government sector healthcare is treated as welfare, which undermines the need for quality. This explains fewer applicants for accreditation to the NABH (National Accreditation Board for Hospitals) from among the government hospitals.

Publication: The Hindu

Edition: Online

Date: September 8, 2014

Headline: [Experimental Ebola vaccine protects monkeys for 10 months](#)

Synopsis: An experimental Ebola vaccine similar to one being developed by GlaxoSmithKline is effective for at least five weeks in lab monkeys but requires boosting with an additional vaccine to extend its protection to 10 months, according to a study published on Sunday. The findings offer an early hint of which, if any, of the Ebola vaccines in development will prove effective, and in what form. Johnson & Johnson and NewLink Genetics are also among the firms accelerating their efforts to provide Ebola vaccines and treatments as the worst known outbreak of the virus ravages West Africa, killing more than 2,000 people.

Publication: The Economic Times

Edition: Online

Date: September 8, 2014

Headline: [Venus Pharma ties up with Mylan for marketing of antibiotic Meropenem](#)

Synopsis: Venus Pharma GmbH, a Germany based wholly owned subsidiary of pharma major Venus Remedies today announced entering into a distribution-cum-outlicensing agreement with world's third largest generic drug maker-Mylan for marketing its antibiotic, Meropenem, in three European countries. The deal with Mylan - headquartered at Cecil Township in Pennsylvania - will enable Venus Remedies to market meropenem in Denmark, Sweden and Finland for a period of five years.

Website: Pharmabiz

Edition: Online

Date: September 8, 2014

Headline: [IDMA & APA to organise Pharmaceutical Analysts' Convention on September 26 & 27 in Mumbai](#)

Synopsis: Indian Drug Manufacturers' Association (IDMA) and Association of the Pharmaceutical Analysts is all set to organise their flagship IDMA-APA Pharmaceutical Analysts' Convention (PAC) on September 26 and 27, 2014 in Mumbai. The Convention which is running its 17th year, will touch base with relevant issues affecting the pharma industry and will provide a platform to bring together industry stalwarts and regulators under one roof.